معرفی
Ben Wijnen is a Researcher at the University of Groningen's Faculty of Science and Engineering within the Department of PharmacoTherapy, Epidemiology and Economics. His work focuses on clinical and pharmacoeconomic aspects of psychosis treatment, with particular emphasis on antipsychotic medication efficacy and outcomes measurement.
His research spans Psychosis, Antipsychotics, Pharmacoeconomics, Epidemiology, and Neuroscience, investigating critical relationships between dopamine D2 receptor affinity and clinical outcomes like negative symptoms and relapse risk in first-episode psychosis. He specializes in translating clinical scales (PANSS, HoNOS) to health economic metrics (EQ-5D) for treatment evaluation.
Recent publications (2024-2025) reveal a concentrated focus on antipsychotic tapering dynamics, neuropharmacological mechanisms of symptom presentation, and health technology assessment methodologies in psychosis care. His work consistently employs large-scale collaborative frameworks to address treatment optimization challenges.
Dr. Wijnen actively contributes to major research consortia including the HAMLETT OPHELIA Consortium and PHAMOUS investigators, driving multi-center studies that integrate clinical neuroscience with pharmacoeconomic analysis to refine psychosis treatment protocols.
